Phibro Animal Health Analyst Ratings
Phibro Animal Health Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/09/2023 | 46.12% | Morgan Stanley | $17 → $16 | Maintains | Equal-Weight |
09/01/2023 | 91.78% | Roth MKM | → $21 | Reiterates | Buy → Buy |
08/31/2023 | 55.25% | Morgan Stanley | $18 → $17 | Maintains | Equal-Weight |
08/29/2023 | 91.78% | Roth MKM | → $21 | Reiterates | Buy → Buy |
07/27/2023 | 64.38% | Morgan Stanley | $18 → $18 | Reiterates | Equal-Weight → Equal-Weight |
05/04/2023 | 64.38% | Morgan Stanley | $19 → $18 | Maintains | Equal-Weight |
02/09/2023 | 73.52% | Morgan Stanley | $20 → $19 | Maintains | Equal-Weight |
12/21/2022 | 64.38% | Roth Capital | → $18 | Initiates Coverage On | → Buy |
11/10/2022 | 82.65% | Morgan Stanley | $21 → $20 | Maintains | Equal-Weight |
09/16/2022 | 55.25% | Barclays | $22 → $17 | Maintains | Underweight |
08/26/2022 | 91.78% | Morgan Stanley | $23 → $21 | Maintains | Equal-Weight |
07/25/2022 | 100.91% | Barclays | → $22 | Downgrades | Equal-Weight → Underweight |
01/10/2022 | 110.05% | Barclays | → $23 | Upgrades | Underweight → Equal-Weight |
11/18/2021 | 110.05% | Morgan Stanley | → $23 | Initiates Coverage On | → Equal-Weight |
07/07/2021 | 110.05% | Barclays | → $23 | Downgrades | Equal-Weight → Underweight |
05/13/2021 | 100.91% | Morgan Stanley | $19 → $22 | Maintains | Underweight |
05/08/2020 | 110.05% | Credit Suisse | $25 → $23 | Maintains | Neutral |
02/06/2020 | — | Gabelli & Co. | Downgrades | Buy → Hold | |
01/28/2020 | 110.05% | Barclays | → $23 | Upgrades | Underweight → Equal-Weight |
09/05/2019 | 91.78% | Morgan Stanley | $30 → $21 | Upgrades | Underweight → Equal-Weight |
08/29/2019 | 64.38% | B of A Securities | $29 → $18 | Reiterates | → Underperform |
08/29/2019 | 64.38% | Barclays | $25 → $18 | Maintains | Underweight |
08/28/2019 | 128.31% | Credit Suisse | $31 → $25 | Reiterates | → Neutral |
06/11/2019 | 128.31% | Barclays | → $25 | Initiates Coverage On | → Underweight |
05/09/2019 | — | Gabelli & Co. | Upgrades | Hold → Buy |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
11/09/2023 | 46.12% | 摩根士丹利 | 17 美元 → 16 美元 | 維護 | 重量相等 |
09/01/2023 | 91.78% | Roth MKM | → 21 美元 | 重申 | 購買 → 購買 |
08/31/2023 | 55.25% | 摩根士丹利 | 18 美元 → 17 美元 | 維護 | 重量相等 |
08/29/2023 | 91.78% | Roth MKM | → 21 美元 | 重申 | 購買 → 購買 |
07/27/2023 | 64.38% | 摩根士丹利 | 18 美元 → 18 美元 | 重申 | 等重 → 等重 |
05/04/2023 | 64.38% | 摩根士丹利 | 19 美元 → 18 美元 | 維護 | 重量相等 |
02/09/2023 | 73.52% | 摩根士丹利 | 20 美元 → 19 美元 | 維護 | 重量相等 |
12/21/2022 | 64.38% | 羅斯資本 | → 18 美元 | 啓動覆蓋範圍開啓 | → 購買 |
2022 年 10 月 11 日 | 82.65% | 摩根士丹利 | 21 美元 → 20 美元 | 維護 | 重量相等 |
2022 年 9 月 16 日 | 55.25% | 巴克萊 | 22 美元 → 17 美元 | 維護 | 體重不足 |
08/26/2022 | 91.78% | 摩根士丹利 | 23 美元 → 21 美元 | 維護 | 重量相等 |
2022 年 7 月 25 日 | 100.91% | 巴克萊 | → 22 美元 | 降級 | 等重 → 減重 |
2022 年 10 月 1 日 | 110.05% | 巴克萊 | → 23 美元 | 升級 | 體重不足 → 重量相等 |
11/18/2021 | 110.05% | 摩根士丹利 | → 23 美元 | 啓動覆蓋範圍開啓 | → 重量相等 |
2021 年 7 月 7 日 | 110.05% | 巴克萊 | → 23 美元 | 降級 | 等重 → 減重 |
2021 年 5 月 13 日 | 100.91% | 摩根士丹利 | 19 美元 → 22 美元 | 維護 | 體重不足 |
05/08/2020 | 110.05% | 瑞士信貸 | 25 美元 → 23 美元 | 維護 | 中立 |
02/06/2020 | — | Gabelli & Co. | 降級 | 買入 → 持有 | |
01/28/2020 | 110.05% | 巴克萊 | → 23 美元 | 升級 | 體重不足 → 重量相等 |
09/05/2019 | 91.78% | 摩根士丹利 | 30 美元 → 21 美元 | 升級 | 體重不足 → 重量相等 |
2019 年 8 月 29 日 | 64.38% | B of A 類證券 | 29 美元 → 18 美元 | 重申 | → 表現不佳 |
2019 年 8 月 29 日 | 64.38% | 巴克萊 | 25 美元 → 18 美元 | 維護 | 體重不足 |
08/28/2019 | 128.31% | 瑞士信貸 | 31 美元 → 25 美元 | 重申 | → 中立 |
2019 年 11 月 6 日 | 128.31% | 巴克萊 | → 25 美元 | 啓動覆蓋範圍開啓 | → 體重不足 |
05/09/2019 | — | Gabelli & Co. | 升級 | 持有 → 買入 |
What is the target price for Phibro Animal Health (PAHC)?
輝寶動物健康(PAHC)的目標價格是多少?
The latest price target for Phibro Animal Health (NASDAQ: PAHC) was reported by Morgan Stanley on November 9, 2023. The analyst firm set a price target for $16.00 expecting PAHC to rise to within 12 months (a possible 46.12% upside). 9 analyst firms have reported ratings in the last year.
摩根士丹利於2023年11月9日公佈了輝寶動物健康(納斯達克股票代碼:PAHC)的最新目標股價。該分析公司將目標股價定爲16.00美元,預計PAHC將在12個月內升至12個月內(可能上漲46.12%)。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Phibro Animal Health (PAHC)?
Phibro Animal Health(PAHC)的最新分析師評級是多少?
The latest analyst rating for Phibro Animal Health (NASDAQ: PAHC) was provided by Morgan Stanley, and Phibro Animal Health maintained their equal-weight rating.
Phibro Animal Health(納斯達克股票代碼:PAHC)的最新分析師評級由摩根士丹利提供,輝寶動物健康維持其同等權重評級。
When is the next analyst rating going to be posted or updated for Phibro Animal Health (PAHC)?
Phibro Animal Health(PAHC)的下一次分析師評級將在何時發佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Phibro Animal Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Phibro Animal Health was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Phibro Animal Health的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級,因此每家公司每年應該獲得4次評級。Phibro Animal Health的最新評級是在2023年11月9日發佈的,因此您應該預計下一個評級將在2024年11月9日左右公佈。
Is the Analyst Rating Phibro Animal Health (PAHC) correct?
分析師對 Phibro 動物健康(PAHC)的評級是否正確?
While ratings are subjective and will change, the latest Phibro Animal Health (PAHC) rating was a maintained with a price target of $17.00 to $16.00. The current price Phibro Animal Health (PAHC) is trading at is $10.95, which is out of the analyst's predicted range.
儘管評級是主觀的,並且會發生變化,但最新的Phibro動物健康(PAHC)評級保持不變,目標股價爲17.00美元至16.00美元。Phibro Animal Health(PAHC)目前的交易價格爲10.95美元,超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。